Press Releases

~ Rapid progress with drug discovery portfolio and ground-breaking findings in inflammation and neurodegeneration ~

4th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the identification of multiple new drug targets in the areas of inflammation and neurodegeneration.

4th May, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces that Clive Dix has been appointed Chief Executive Officer with immediate effect.

Thursday, 17 March 2016

Interim Results

17 March, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces its interim unaudited results for the six months ended 31 January 2016.

Corporate highlights

  • Dr Clive Dix appointed as Executive Chairman to implement strategy of building the world’s most productive drug discovery and development company.
  • Significant progress across therapeutic programmes:
    • Addiction: oral drug candidate from the Orexin-1 programme for the treatment of addictive disorders such as nicotine addiction, continues to progress through preclinical development. Potential imaging agent for planned Phase I study identified. Second, differentiated Orexin-1 antagonist identified as follow-up candidate.
    • Inflammation: design of novel oral activators of the NRF-2 pathway which is important in lung diseases with high unmet medical need such as Chronic Obstructive Pulmonary Disease (“COPD”); identification of small molecule inhibitors of the IL-17 pathway implicated in multiple inflammatory and autoimmune diseases including psoriasis.
    • Diabetes: identification of novel, potent, orally available lead molecules activating GPR142 a key factor in the production of insulin.
  • Collaboration established with University of Oxford’s Structural Genomics Consortium (“SGC-Oxford”) to improve and identify potent and selective molecules against a range of targets and initiation of an oncology therapeutic programme.
  • Refinement of hybrid business model of wholly owned pipeline of drug discovery programmes plus partnerships with Pharma and Biotech. Access to C4XD proprietary technologies on a fee for service basis to be discontinued to maximise internal resource available for value creating pipeline projects. Aim to transition current fee-for-service relationships to shared IP or milestone driven collaborative agreements.

Adorial Limited augments C4X Discovery’s drug discovery engine

1 March, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of Adorial Limited together with its subsidiaries ("Adorial"), a privately held drug discovery company with a proprietary genetic technology platform for the identification of novel drug targets ("the Acquisition").

19 November, 2015 – C4X Discovery Holdings plc (“C4XD” or the “Company”), a leader in rational drug discovery and design, today announces the appointment of Dr Clive Dix as Executive Chairman.

6 November, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, announces that in accordance with AIM Rule 20, electronic copies of its Annual Report and Accounts for the year ended 31 July 2015 together with the Notice of Annual General Meeting and Form of Proxy are available from the Company's investor relations website at www.c4xdiscovery.com. Hard copies of the 2015 Annual Report and Accounts have been posted to shareholders today.

28 October, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to announce that it has entered into a research collaboration with the University of Oxford’s Structural Genomics Consortium department (“SGC-Oxford”).

28 October, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to announce its preliminary results for the year ended 31 July 2015.